Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026

Core Viewpoint - Valneva SE, a specialty vaccine company, will report its full year 2025 financial results on March 18, 2026, and will host a live webcast to discuss these results and provide a business update [1]. Company Overview - Valneva SE develops, manufactures, and commercializes prophylactic vaccines for infectious diseases, focusing on unmet medical needs with a specialized approach [3]. - The company has a strong track record of advancing multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [4]. Financial and Business Insights - Revenues from Valneva's growing commercial business support the advancement of its vaccine pipeline, which includes the only Lyme disease vaccine candidate in advanced clinical development partnered with Pfizer, and the world's most clinically advanced Shigella vaccine candidate [5].